ALVR

AlloVir, Inc. (ALVR) | Rumor.io

AlloVir

ALVR

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization14.7M

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-58.8M

Social

What share of all stock conversation is about ALVR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 16

AlloVir, Inc. (ALVR) announced a stock split.
There is speculation that ALVR's stock price is about to increase.
ALVR's CEO, Diana Brainard, has stepped down.

Generated by AI

Sentiment

Of the messages about ALVR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +31.9
Bearish	—	—	—	0% -31.9

Bullish· Aug 21

ALVR has shown a 26% return with a potential 1-year target of $18, and a 49% increase from its ATH.
Analysts at Bank of America have given ALVR a buy rating, indicating a potential increase in value.
A well-placed stop loss can act as a safety net for ALVR, protecting capital and potentially leading to a fruitful outcome if the stock experiences a surge in value.

Bearish· Dec 22

AlloVir's shares plummeted 64% after the company announced it would discontinue three late-stage studies evaluating its antiviral cell therapy, posoleucel.
The company's decision to stop its Phase 3 trials for its lead product led to a significant decline in its stock value, with some investors experiencing substantial losses.
AlloVir's management has been criticized for its handling of the situation, with some accusing the company of making misleading statements and potentially profiting from the stock's decline.

Generated by AI

Topics

Of the messages about ALVR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	77.27%
Controversies	—	—	—	18.18%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	4.55%

Announcements· Jan 16

AlloVir, Inc. (ALVR) announced a stock split with a ratio of 1-23.
Trading of ALVR will resume on NASDAQ on January 16, 2025, at 09:00:00 ET.
The company did not provide further details on the stock split.

Technical Analysis· Feb 11

$ALVR enters an uptrend as momentum indicator exceeded the 0 level on February 5, 2021.
View odds for this and other indicators.
This post is primarily about technical analysis of ALVR.

Generated by AI

Community

Of the messages about ALVR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	18.52%
Newcomers	—	—	—	81.48%

Regulars· Mar 17

AlloVir, Inc. (ALVR) is mentioned as one of the stocks that could benefit from a $1 trillion market cap, according to a recent article by Oracle.
The company's stock price is not directly discussed, but it is mentioned alongside other tech stocks in articles about the AI industry and its potential.
AlloVir, Inc. (ALVR) is one of the stocks that could be a good fit for a long-term passive income investment, according to an article by Benzinga.

Newcomers· Dec 22

New investors are focused on the recent price drop of AlloVir's stock, with some mentioning a haircut of up to 61% pre-market.
The company's decision to discontinue its three phase 3 studies for Posoleucel, a virus-specific T-cell therapy, is the main concern for new investors, as it may impact the stock's value.
Investors are also considering the potential implications of the company's decision to discontinue the studies, with some speculating about strategic alternatives and the biotech industry's current market trends.

Generated by AI

Also Discussed

Investors talking about ALVR also mention

#	Name	Attention
1	Nkarta, Inc.NKTX	0%0
2	Pliant Therapeutics Inc.PLRX	0%0
3	RPHM - Reneo Pharmaceuticals, Inc.	——
4	ImageneBio, Inc.IKNA	0%0
5	IGMS - IGM Biosciences, Inc.	——
6	FRGE - Forge Global Holdings, Inc.	——
7	Nutex Health Inc.NUTX	0%new
8	Veru Inc.VERU	0%0
9	FNCH - Finch Therapeutics Group, Inc.	——
10	Atara Biotherapeutics, Inc.ATRA	0%0

AlloVir, Inc.

Healthcare
Biotechnology

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases with major unmet medical needs. The company’s lead program is TH103, an investigational anti-VEGF therapy designed for exudative and neovascular retinal conditions, including neovascular age-related macular degeneration. Kalaris Therapeutics also works on extending TH103’s use across other retinal disorders such as diabetic macular edema and retinal vein occlusion. Its current business centers on ophthalmology and biotechnology, where it aims to address sight-threatening diseases through targeted retinal therapies. The company is headquartered in the United States and operates as a specialist developer within the broader healthcare market.

Website

Location

400 Connell Drive

Berkeley Heights, NJ, 07922

United States

Social

What share of all stock conversation is about ALVR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 16

AlloVir, Inc. (ALVR) announced a stock split.
There is speculation that ALVR's stock price is about to increase.
ALVR's CEO, Diana Brainard, has stepped down.

Generated by AI

Sentiment

Of the messages about ALVR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +31.9
Bearish	—	—	—	0% -31.9

Bullish· Aug 21

ALVR has shown a 26% return with a potential 1-year target of $18, and a 49% increase from its ATH.
Analysts at Bank of America have given ALVR a buy rating, indicating a potential increase in value.
A well-placed stop loss can act as a safety net for ALVR, protecting capital and potentially leading to a fruitful outcome if the stock experiences a surge in value.

Bearish· Dec 22

AlloVir's shares plummeted 64% after the company announced it would discontinue three late-stage studies evaluating its antiviral cell therapy, posoleucel.
The company's decision to stop its Phase 3 trials for its lead product led to a significant decline in its stock value, with some investors experiencing substantial losses.
AlloVir's management has been criticized for its handling of the situation, with some accusing the company of making misleading statements and potentially profiting from the stock's decline.

Generated by AI

Topics

Of the messages about ALVR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	77.27%
Controversies	—	—	—	18.18%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	4.55%

Announcements· Jan 16

AlloVir, Inc. (ALVR) announced a stock split with a ratio of 1-23.
Trading of ALVR will resume on NASDAQ on January 16, 2025, at 09:00:00 ET.
The company did not provide further details on the stock split.

Technical Analysis· Feb 11

$ALVR enters an uptrend as momentum indicator exceeded the 0 level on February 5, 2021.
View odds for this and other indicators.
This post is primarily about technical analysis of ALVR.

Generated by AI

Community

Of the messages about ALVR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	18.52%
Newcomers	—	—	—	81.48%

Regulars· Mar 17

AlloVir, Inc. (ALVR) is mentioned as one of the stocks that could benefit from a $1 trillion market cap, according to a recent article by Oracle.
The company's stock price is not directly discussed, but it is mentioned alongside other tech stocks in articles about the AI industry and its potential.
AlloVir, Inc. (ALVR) is one of the stocks that could be a good fit for a long-term passive income investment, according to an article by Benzinga.

Newcomers· Dec 22

New investors are focused on the recent price drop of AlloVir's stock, with some mentioning a haircut of up to 61% pre-market.
The company's decision to discontinue its three phase 3 studies for Posoleucel, a virus-specific T-cell therapy, is the main concern for new investors, as it may impact the stock's value.
Investors are also considering the potential implications of the company's decision to discontinue the studies, with some speculating about strategic alternatives and the biotech industry's current market trends.

Generated by AI

AlloVir

Social

Jan 16

Sentiment

Bullish· Aug 21

Bearish· Dec 22

Topics

Announcements· Jan 16

Technical Analysis· Feb 11

Community

Regulars· Mar 17

Newcomers· Dec 22

Also Discussed

AlloVir, Inc.

Company Information

Location

Also Discussed

Social

Jan 16

Sentiment

Bullish· Aug 21

Bearish· Dec 22

Topics

Announcements· Jan 16

Technical Analysis· Feb 11

Community

Regulars· Mar 17

Newcomers· Dec 22